A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer

Annals of Oncology

Volumn 21, Issue 5, 2009, Pages 1020-1026

  Glimelius, B ^a,b   Lahn, M ^c   Gawande, S ^c   Cleverly, A ^c   Darstein, C ^c   Musib, L ^c   Liu, Y ^d   Spindler, K L ^e   Frodin J E ^b   Berglund, A ^a   Bystrom P ^b   Qvortrup, C ^f   Jakobsen, A ^e   Pfeiffer, P ^f  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ELI LILLY AND COMPANY   (United States)

^d I3Statprobe Inc   (United States)

^e LILLEBAELT HOSPITAL   (Denmark)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Asymptomatic; Chemonaive; Enzastaurin; Metastatic colorectal cancer; Window study

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; ENZASTAURIN; LACTATE DEHYDROGENASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RIGOR; SIDE EFFECT; SURVIVAL RATE; XEROSTOMIA;

EID: 77951235239     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp521     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 2007; 8: 898-911.
3. Norrby K. Angiogenesis: new aspects relating to its initiation and control. APMIS 1997; 105: 417-437.
4. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
5. Gokmen-Polar Y, Murray NR, Velasco MA et al. Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. Cancer Res 2001; 61: 1375-1381.
6. Graff JR, McNulty AM, Hanna KR et al. The protein kinase C beta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT original article pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005; 65: 7462-7469.
7. Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS. Phase I clinical trial design in cancer drug development. J Clin Oncol 2000; 18: 684-692.
8. Ettinger DS, Finkelstein DM, Abeloff MD et al. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study. J Natl Cancer Inst 1992; 84: 1077-1084.
9. Gore SD, Rowinsky EK, Miller CB et al. A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. Clin Cancer Res 1998; 4: 2677-2689.
10. Johnson BE, Fischer T, Fischer B et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003; 9: 5880-5887.
11. Lager JJ, Lyden ER, Anderson JR et al. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2006; 24: 3415-3422.
12. Glimelius B. Palliative treatment of patients with colorectal cancer. Scand J Surg 2003; 92: 74-83.
13. Ackland SP, Jones M, Tu D et al. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Br J Cancer 2005; 93: 1236-1243.
14. Nordlinger B, Van Cutsem E, Gruenberger T et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009; 20: 985-992.
15. Sorbye H, Kohne CH, Sargent DJ, Glimelius B. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol 2007; 18: 1666-1672.
16. Kohne CH, Cunningham D, Di Costanzo F et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317.
17. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
18. Welch PA, Sinha VP, Cleverly AL et al. Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects. J Clin Pharmacol 2007; 47: 1138-1151.
19. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992; 10: 904-911.
20. Kreisl TN, Kim L, Moore K et al. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res 2009; 15: 3617-3623.
21. Robertson MJ, Kahl BS, Vose JM et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007; 25: 1741-1746.
22. ICH Guidance for Industry E14: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. United States Food and Drug Administration 2002 http://www.fda.gov/ohrms/dockets/ac/03/briefing/3956B3951_3902_FDA-Preliminary%3920Concept.doc (1 November 2009, date last accessed).
23. Dmitrienko A, Beasley C, Mitchell M. Design and analysis of thorough QT studies. In Chuang-Stein C, D'Agostino R, Dmitrienko A (eds) Biopharmaceutical Network. Edition Report 2008-04-29. Biopharmaceutical Network 2008; http://www.biopharmnet.com/cardiac.html (1 November 2009, date last accessed).
24. Ma H, Smith B, Dmitrienko A. Statistical analysis methods for QT/QTc prolongation. J Biopharm Stat 2008; 18: 553-563.
25. Carducci MA, Musib L, Kies MS et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006; 24: 4092-4099.
26. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850.
27. Gustavsson B, Kaiser C, Carlsson G et al. Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes. Int J Cancer 2009; 124: 1220-1226.
28. Garm Spindler K-L, Lindebjerg J, Lahn M et al. Protein kinase C-beta II (PKC-bII) expression in patients with colorectal cancer. Int J Colorectal Dis 2009; 24(6): 641-645.
29. Glimelius B, Spindler KL, Frödin J-E et al. Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study. Ann Oncol 2009; doi:10.1093/annonc/mdp526.
30. Bast RC Jr, Ravdin P, Hayes DF et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865-1878.
31. Fletcher JW, Djulbegovic B, Soares HP et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008; 49: 480-508.
32. 18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol 2009; 20: 1057-1061.
33. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT Interval. J Clin Oncol 2007; 25: 3362-3371.
34. Curigliano G, Spitaleri G, Fingert HJ et al. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur J Cancer 2008; 44: 494-500.
35. Watkins V, Hong S, Lin BK. Enzastaurin safety review: data from phase I and phase II trials. J Clin Oncol 2006; 24: (Abstr 13077).
36. Ouaret D, Kamsu-Kom N, Bigot L et al. The selective protein kinase C beta II (PKC beta II) inhibitor enzastaurin (Enza), is a potent inhibitor of angiogenesis and lymphoangiogenesis in colorectal cancer (CRC) models. Ann Oncol 2009; 20 (Suppl 7), vi30.